# 📖 EXTRACTION PIECE 2.2: Manager Approval Process
**Source**: Lines 5107-5200 of `2025-11-19_09-12Z-designing-zero-tolerance-content-filtering-layer.md`  
**Date Extracted**: 2025-01-20  
**Status**: ✅ Complete

---

## 📋 SUMMARY

This section documents what the manager needed to approve for Phase 2, the manager's concrete answers, and the specific selections made. This is critical for understanding the validation scope and resource allocation decisions.

---

## 🔍 KEY FINDINGS

### **What Manager Needed to Approve for Phase 2**

#### **1. Start Cohort-Level SAE Analysis**
- Extract SAE features for labeled patient cohorts (TCGA-OV, MM, etc.)
- Run correlation analysis: which of the 32K SAE features correlate with outcomes?
- Build `scripts/extract_sae_features_cohort.py`
- Build `api/services/biomarker_correlation_service.py`

#### **2. Validation Scope & Criteria**
- **Cohort size:** Start with N=100-200 patients (small, focused)
- **Outcome:** Which to test first? (e.g., platinum resistance, rwPFS 2-class, OS)
- **Success criteria:** Top-N features (e.g., 10-20) with:
  - Pearson correlation > 0.3 or p-value < 0.05
  - Plausible biology (cross-reference with known pathways)
  - Stable across cross-validation splits

#### **3. Resource Allocation**
- **Compute:** GPU time for extracting SAE features for 100-200 patients × ~20-50 variants each = ~2K-10K SAE extractions
- **Timeline:** Phase 2 estimated at 3-4 weeks
- **Priority:** Is this higher priority than other pending tasks?

---

### **Manager's Concrete Answers**

**Manager's Response (model gpt-5):**

> "Yes. Approvals needed and my concrete selections:"

#### **Outcome to Validate First**
- **Selection**: TCGA Ovarian platinum response (binary)
- **Rationale**: Ground truth exists via `scripts/extract_platinum_response_labels.py`
- **Restriction**: Restrict to patients with complete labels

#### **Cohort**
- **Selection**: TCGA-OV
- **Start**: N≈200 fully labeled cases
- **Expand**: To full 469 after sanity checks

#### **Success Criteria**
- **Top-20 SAE features** with:
  - p < 0.05
  - Cross-validated stability
  - Plausible biology mapping (DDR/MAPK/IO clusters)
- **No production lifts** until hold-out gains confirmed

#### **Compute/Resources**
- **Hardware**: Evo2 1B + SAE on GPU (H100)
- **Scale**: ~200 pts × ~30 variants ≈ 6K extractions
- **Performance**: Per variant 50–150 ms
- **Wall-time**: ~10–20 min with modest parallelism
- **Platform**: OK to run within current Modal pattern

#### **Build Scope (Phase 2)**
- `scripts/extract_sae_features_cohort.py` (batch Evo2 activations → SAE features)
- `api/services/biomarker_correlation_service.py` (feature↔outcome stats + CV)

---

### **What Manager Does NOT Need to Approve Yet**

✅ **Phase 1 is complete and safe:**
- All infrastructure is built and gated behind flags
- No production behavior changes
- Everything is diagnostics-only
- Full provenance tracking in place

✅ **Phase 3 decisions are deferred:**
- Using SAE features to influence WIWFM/resistance scoring
- Adding SAE-based lifts to clinical predictions
- These decisions only come AFTER Phase 2 validation shows clear, stable benefit

---

### **Recommended Manager Question**

**Original Question:**
> "Should Zo proceed with Phase 2: cohort-level SAE feature extraction and correlation analysis to identify which SAE features (out of 32K) actually correlate with clinical outcomes? If yes, which outcome should we validate first: platinum resistance (TCGA-OV), MM drug response, or another?"

**Manager's Answer:**
- ✅ Yes, proceed
- ✅ Outcome: TCGA Ovarian platinum response
- ✅ Cohort: TCGA-OV, N≈200
- ✅ Success: Top-20 features, p<0.05, CV stability, plausible biology
- ✅ Resources: Approved (H100 GPU, Modal pattern)

---

## 📊 KEY INSIGHTS

### **Manager's Decision-Making**

1. **Concrete Selections**: Manager provided specific answers, not vague approvals
2. **Validation-First**: No production changes until validation confirms benefit
3. **Incremental**: Start with N≈200, expand to full 469 after checks
4. **Rigorous Criteria**: p<0.05, CV stability, plausible biology
5. **Resource-Aware**: Approved compute resources and timeline

### **Approval Process**

1. **Clear Scope**: What needs approval vs what doesn't
2. **Specific Criteria**: Success metrics defined upfront
3. **Resource Allocation**: Compute and timeline approved
4. **Build Scope**: Exact files to be built specified
5. **Deferred Decisions**: Phase 3 explicitly deferred

---

## 🔗 CONTEXT & CONNECTIONS

- **Builds on**: Phase 1 completion (Piece 2.1)
- **Enables**: Phase 2 execution (cohort extraction and biomarker analysis)
- **Defines**: Validation scope, success criteria, resources
- **Key Insight**: Manager provided concrete, actionable approvals

---

## 📝 NOTES

- Manager's answers were specific and actionable
- Validation scope is clearly defined
- Success criteria are rigorous but achievable
- Resources are approved and sufficient
- Phase 3 is explicitly deferred until validation

---

## 🎯 QUESTIONS RESOLVED

- ✅ What does manager need to approve? → Phase 2 scope, validation criteria, resources
- ✅ What outcome to validate? → TCGA Ovarian platinum response (binary)
- ✅ What cohort size? → N≈200 to start, expand to 469
- ✅ What are success criteria? → Top-20 features, p<0.05, CV stability, plausible biology
- ✅ What resources approved? → H100 GPU, Modal pattern, ~10-20 min runtime

